COVID-19 Impact on Global Neurometabolic Disorders Market Size, Status and Forecast 2020-2026

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Neurometabolic Disorders Revenue
• 1.4 Market Analysis by Type
  • 1.4.1 Global Neurometabolic Disorders Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Gaucher’s Disease
  • 1.4.3 Fabry Disease
  • 1.4.4 Pompe Disease
  • 1.4.5 Mucopolysaccharidosis VI
  • 1.4.6 Other
• 1.5 Market by Application
  • 1.5.1 Global Neurometabolic Disorders Market Share by Application: 2020 VS 2026
  • 1.5.2 Oral
  • 1.5.3 Parenteral
• 1.6 Coronavirus Disease 2019 (Covid-19): Neurometabolic Disorders Industry Impact
  • 1.6.1 How the Covid-19 is Affecting the Neurometabolic Disorders Industry
    • 1.6.1.1 Neurometabolic Disorders Business Impact Assessment - Covid-19
    • 1.6.1.2 Supply Chain Challenges
    • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  • 1.6.2 Market Trends and Neurometabolic Disorders Potential Opportunities in the COVID-19 Landscape
  • 1.6.3 Measures / Proposal against Covid-19
    • 1.6.3.1 Government Measures to Combat Covid-19 Impact
    • 1.6.3.2 Proposal for Neurometabolic Disorders Players to Combat Covid-19 Impact
• 1.7 Study Objectives
• 1.8 Years Considered

2 Global Growth Trends by Regions

• 2.1 Neurometabolic Disorders Market Perspective (2015-2026)
• 2.2 Neurometabolic Disorders Growth Trends by Regions
  • 2.2.1 Neurometabolic Disorders Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Neurometabolic Disorders Historic Market Share by Regions (2015-2020)
  • 2.2.3 Neurometabolic Disorders Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Neurometabolic Disorders Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Neurometabolic Disorders Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Neurometabolic Disorders Players by Market Size
  • 3.1.1 Global Top Neurometabolic Disorders Players by Revenue (2015-2020)
  • 3.1.2 Global Neurometabolic Disorders Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Neurometabolic Disorders Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Neurometabolic Disorders Market Concentration Ratio
  • 3.2.1 Global Neurometabolic Disorders Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Neurometabolic Disorders Revenue in 2019
• 3.3 Neurometabolic Disorders Key Players Head office and Area Served
• 3.4 Key Players Neurometabolic Disorders Product Solution and Service
• 3.5 Date of Enter into Neurometabolic Disorders Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

• 4.1 Global Neurometabolic Disorders Historic Market Size by Type (2015-2020)
• 4.2 Global Neurometabolic Disorders Forecasted Market Size by Type (2021-2026)

5 Neurometabolic Disorders Breakdown Data by Application (2015-2026)

• 5.1 Global Neurometabolic Disorders Market Size by Application (2015-2020)
• 5.2 Global Neurometabolic Disorders Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Neurometabolic Disorders Market Size (2015-2020)
• 6.2 Neurometabolic Disorders Key Players in North America (2019-2020)
• 6.3 North America Neurometabolic Disorders Market Size by Type (2015-2020)
• 6.4 North America Neurometabolic Disorders Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Neurometabolic Disorders Market Size (2015-2020)
• 7.2 Neurometabolic Disorders Key Players in Europe (2019-2020)
• 7.3 Europe Neurometabolic Disorders Market Size by Type (2015-2020)
• 7.4 Europe Neurometabolic Disorders Market Size by Application (2015-2020)

8 China

• 8.1 China Neurometabolic Disorders Market Size (2015-2020)
• 8.2 Neurometabolic Disorders Key Players in China (2019-2020)
• 8.3 China Neurometabolic Disorders Market Size by Type (2015-2020)
• 8.4 China Neurometabolic Disorders Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Neurometabolic Disorders Market Size (2015-2020)
• 9.2 Neurometabolic Disorders Key Players in Japan (2019-2020)
• 9.3 Japan Neurometabolic Disorders Market Size by Type (2015-2020)
• 9.4 Japan Neurometabolic Disorders Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Neurometabolic Disorders Market Size (2015-2020)
• 10.2 Neurometabolic Disorders Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Neurometabolic Disorders Market Size by Type (2015-2020)
• 10.4 Southeast Asia Neurometabolic Disorders Market Size by Application (2015-2020)

11 India

• 11.1 India Neurometabolic Disorders Market Size (2015-2020)
• 11.2 Neurometabolic Disorders Key Players in India (2019-2020)
• 11.3 India Neurometabolic Disorders Market Size by Type (2015-2020)
• 11.4 India Neurometabolic Disorders Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Neurometabolic Disorders Market Size (2015-2020)
• 12.2 Neurometabolic Disorders Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Neurometabolic Disorders Market Size by Type (2015-2020)
• 12.4 Central & South America Neurometabolic Disorders Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 Amicus Therapeutics
  • 13.1.1 Amicus Therapeutics Company Details
  • 13.1.2 Amicus Therapeutics Business Overview and Its Total Revenue
  • 13.1.3 Amicus Therapeutics Neurometabolic Disorders Introduction
  • 13.1.4 Amicus Therapeutics Revenue in Neurometabolic Disorders Business (2015-2020))
  • 13.1.5 Amicus Therapeutics Recent Development
• 13.2 ISU Abxis
  • 13.2.1 ISU Abxis Company Details
  • 13.2.2 ISU Abxis Business Overview and Its Total Revenue
  • 13.2.3 ISU Abxis Neurometabolic Disorders Introduction
  • 13.2.4 ISU Abxis Revenue in Neurometabolic Disorders Business (2015-2020)
  • 13.2.5 ISU Abxis Recent Development
• 13.3 JCR Pharmaceuticals
  • 13.3.1 JCR Pharmaceuticals Company Details
  • 13.3.2 JCR Pharmaceuticals Business Overview and Its Total Revenue
  • 13.3.3 JCR Pharmaceuticals Neurometabolic Disorders Introduction
  • 13.3.4 JCR Pharmaceuticals Revenue in Neurometabolic Disorders Business (2015-2020)
  • 13.3.5 JCR Pharmaceuticals Recent Development
• 13.4 Biosidus
  • 13.4.1 Biosidus Company Details
  • 13.4.2 Biosidus Business Overview and Its Total Revenue
  • 13.4.3 Biosidus Neurometabolic Disorders Introduction
  • 13.4.4 Biosidus Revenue in Neurometabolic Disorders Business (2015-2020)
  • 13.4.5 Biosidus Recent Development
• 13.5 Greenovation Biotech
  • 13.5.1 Greenovation Biotech Company Details
  • 13.5.2 Greenovation Biotech Business Overview and Its Total Revenue
  • 13.5.3 Greenovation Biotech Neurometabolic Disorders Introduction
  • 13.5.4 Greenovation Biotech Revenue in Neurometabolic Disorders Business (2015-2020)
  • 13.5.5 Greenovation Biotech Recent Development
• 13.6 UAB Proforma
  • 13.6.1 UAB Proforma Company Details
  • 13.6.2 UAB Proforma Business Overview and Its Total Revenue
  • 13.6.3 UAB Proforma Neurometabolic Disorders Introduction
  • 13.6.4 UAB Proforma Revenue in Neurometabolic Disorders Business (2015-2020)
  • 13.6.5 UAB Proforma Recent Development
• 13.7 Dong-A Socio Group
  • 13.7.1 Dong-A Socio Group Company Details
  • 13.7.2 Dong-A Socio Group Business Overview and Its Total Revenue
  • 13.7.3 Dong-A Socio Group Neurometabolic Disorders Introduction
  • 13.7.4 Dong-A Socio Group Revenue in Neurometabolic Disorders Business (2015-2020)
  • 13.7.5 Dong-A Socio Group Recent Development
• 13.8 ExSAR Corporation
  • 13.8.1 ExSAR Corporation Company Details
  • 13.8.2 ExSAR Corporation Business Overview and Its Total Revenue
  • 13.8.3 ExSAR Corporation Neurometabolic Disorders Introduction
  • 13.8.4 ExSAR Corporation Revenue in Neurometabolic Disorders Business (2015-2020)
  • 13.8.5 ExSAR Corporation Recent Development
• 13.9 Lixte Biotechnology
  • 13.9.1 Lixte Biotechnology Company Details
  • 13.9.2 Lixte Biotechnology Business Overview and Its Total Revenue
  • 13.9.3 Lixte Biotechnology Neurometabolic Disorders Introduction
  • 13.9.4 Lixte Biotechnology Revenue in Neurometabolic Disorders Business (2015-2020)
  • 13.9.5 Lixte Biotechnology Recent Development
• 13.10 Neuraltus Pharmaceuticals
  • 13.10.1 Neuraltus Pharmaceuticals Company Details
  • 13.10.2 Neuraltus Pharmaceuticals Business Overview and Its Total Revenue
  • 13.10.3 Neuraltus Pharmaceuticals Neurometabolic Disorders Introduction
  • 13.10.4 Neuraltus Pharmaceuticals Revenue in Neurometabolic Disorders Business (2015-2020)
  • 13.10.5 Neuraltus Pharmaceuticals Recent Development
• 13.11 Protalix
  • 10.11.1 Protalix Company Details
  • 10.11.2 Protalix Business Overview and Its Total Revenue
  • 10.11.3 Protalix Neurometabolic Disorders Introduction
  • 10.11.4 Protalix Revenue in Neurometabolic Disorders Business (2015-2020)
  • 10.11.5 Protalix Recent Development
• 13.12 Pharming Group
  • 10.12.1 Pharming Group Company Details
  • 10.12.2 Pharming Group Business Overview and Its Total Revenue
  • 10.12.3 Pharming Group Neurometabolic Disorders Introduction
  • 10.12.4 Pharming Group Revenue in Neurometabolic Disorders Business (2015-2020)
  • 10.12.5 Pharming Group Recent Development
• 13.13 Protalix BioTherapeutics
  • 10.13.1 Protalix BioTherapeutics Company Details
  • 10.13.2 Protalix BioTherapeutics Business Overview and Its Total Revenue
  • 10.13.3 Protalix BioTherapeutics Neurometabolic Disorders Introduction
  • 10.13.4 Protalix BioTherapeutics Revenue in Neurometabolic Disorders Business (2015-2020)
  • 10.13.5 Protalix BioTherapeutics Recent Development
• 13.14 Amicus
  • 10.14.1 Amicus Company Details
  • 10.14.2 Amicus Business Overview and Its Total Revenue
  • 10.14.3 Amicus Neurometabolic Disorders Introduction
  • 10.14.4 Amicus Revenue in Neurometabolic Disorders Business (2015-2020)
  • 10.14.5 Amicus Recent Development
• 13.15 Biomarin
  • 10.15.1 Biomarin Company Details
  • 10.15.2 Biomarin Business Overview and Its Total Revenue
  • 10.15.3 Biomarin Neurometabolic Disorders Introduction
  • 10.15.4 Biomarin Revenue in Neurometabolic Disorders Business (2015-2020)
  • 10.15.5 Biomarin Recent Development
• 13.16 Genzyme
  • 10.16.1 Genzyme Company Details
  • 10.16.2 Genzyme Business Overview and Its Total Revenue
  • 10.16.3 Genzyme Neurometabolic Disorders Introduction
  • 10.16.4 Genzyme Revenue in Neurometabolic Disorders Business (2015-2020)
  • 10.16.5 Genzyme Recent Development
• 13.17 Shire
  • 10.17.1 Shire Company Details
  • 10.17.2 Shire Business Overview and Its Total Revenue
  • 10.17.3 Shire Neurometabolic Disorders Introduction
  • 10.17.4 Shire Revenue in Neurometabolic Disorders Business (2015-2020)
  • 10.17.5 Shire Recent Development
• 13.18 Greencross
  • 10.18.1 Greencross Company Details
  • 10.18.2 Greencross Business Overview and Its Total Revenue
  • 10.18.3 Greencross Neurometabolic Disorders Introduction
  • 10.18.4 Greencross Revenue in Neurometabolic Disorders Business (2015-2020)
  • 10.18.5 Greencross Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer